Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00318214 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy Study of MRE0094 to Treat Large, Single or Multiple, Chronic, Neuropathic, Diabetic Foot Ulcers

A Phase 2 study, sponsored by Pfizer.

Terminated
Registry status
Phase 2
Development phase
16
Enrollment target

NCT00318214 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 16 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00318214, a Phase 2 study, was terminated before completion, sponsored by Pfizer.

TERMINATED
Registry status
Phase 2
Development phase
16 participants
Enrollment target

Study Summary

This is a clinical research study of an experimental topical drug for the treatment of chronic, neuropathic, diabetic foot ulcers. The purpose of the study is to determine the safety of the experimental drug when applied to large, diabetic foot ulcers. The study will also determine if the experimental drug can safely promote healing of diabetic foot ulcers better than standard treatments currently available to doctors. Patients participating in the study may receive an active drug (MRE0094) or inactive drug (placebo). What treatment a patient will receive is determined by chance (like drawing a number from a hat). All patients will receive additional care for diabetic foot ulcers during the study. Participation in the study can be up to 4½ months.

Interventions

  • DRUG Vehicle gel
  • DRUG MRE0094

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2006-06
Est. Completion 2008-02
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT00318214

The ClinicalTrials.gov registry entry for NCT00318214 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Vehicle gel is the first listed.

NCT00318214 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00318214 about?

NCT00318214 is a clinical study titled "Safety and Efficacy Study of MRE0094 to Treat Large, Single or Multiple, Chronic, Neuropathic, Diabetic Foot Ulcers". This is a clinical research study of an experimental topical drug for the treatment of chronic, neuropathic, diabetic foot ulcers. The purpose of the study is to determine the safety of the experimental drug when applied to large, diabetic foot ulcers. The study will also determine if the experiment...

What is the current status of trial NCT00318214?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2006-06. Estimated completion is 2008-02.

What interventions are being tested in trial NCT00318214?

The interventions under investigation include: Vehicle gel (DRUG), MRE0094 (DRUG).

Who is sponsoring clinical trial NCT00318214?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.